Limitations
nausea, CINV
This study has some limitations. Moving forward, it is critical to validate these results with a larger multicenter randomized clinical trial. Second, a computer-based centralized random assignment instead of sealed envelopes would allow for a more accurate allocation procedure by preventing premature revealing. Third, patients who experienced CINV during the induction phase could have been included in the analysis when evaluating determinants of sustained complete control. In addition, there is need for improvement in control of nausea both prophylactically and as rescue therapy during combined radiotherapy-HEC. Antiemetic regimens, including olanzapine, in chemoradiotherapy should be investigated in future clinical trials, because olanzapine is considered to be particularly effective against nausea.